Please use this identifier to cite or link to this item:
|Title:||Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey.|
|Citation:||Allergy Asthma Clin Immunol.2017;(13):31|
|Abstract:||Patients with hereditary angioedema (HAE) due to C1-inhibitor deficiency (C1-INH-HAE) experience recurrent attacks of cutaneous or submucosal edema that may be frequent and severe; prophylactic treatments can be prescribed to prevent attacks. However, despite the use of long-term prophylaxis (LTP), breakthrough attacks are known to occur. We used data from the Icatibant Outcome Survey (IOS) to evaluate the characteristics of breakthrough attacks and the effectiveness of icatibant as a treatment option.|
|Appears in Collections:||Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos|
Hospitales > H. U. La Paz > Artículos
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.